BioMarin Pharmaceuticals (BMRN)

BioMarin’s approved therapies address disorders including phenylketonuria, mucopolysaccharidosis, neuronal ceroid lipofuscinosis, achondroplasia and haemophilia A. Its products include enzyme replacement therapies, oral small-molecule treatments, biologics and gene therapy. Voxzogo, for children with achondroplasia, and Roctavian, a gene therapy for severe haemophilia A, are among the company’s more prominent recent commercial products, while older medicines such as Naglazyme, Vimizim and Brineura form part of its established rare disease portfolio.

The company combines internal research, clinical development, manufacturing and global commercial operations. Because rare disease therapies often require complex biologic production and close relationships with specialist physicians and patient communities, BioMarin’s capabilities extend beyond drug discovery into diagnostics, disease education and long-term treatment support.

BioMarin’s investment profile is shaped by the durability of its marketed products, uptake of newer launches, pricing and reimbursement discussions, manufacturing reliability and pipeline progress. Its development programmes focus on additional skeletal conditions, enzyme-related diseases and other genetically defined disorders. For investors, BioMarin offers exposure to the rare disease biotechnology market, where successful therapies can command strong demand but face clinical, regulatory and commercial risks.